Nizatidine

Pregnancy
categoryRoutes of
administrationBy mouthATC codeLegal statusLegal status Pharmacokinetic dataBioavailability>70%Protein binding35%MetabolismLiverElimination half-life1–2 hoursExcretionKidneyIdentifiersCAS NumberPubChem CIDIUPHAR/BPSDrugBankChemSpiderUNIIKEGGChEBIChEMBLCompTox Dashboard (EPA)ECHA InfoCard100.155.683 Chemical and physical dataFormulaC₁₂H₂₁N₅O₂S₂Molar mass331.45 g·mol⁻¹3D model (JSmol) ^NY (what is this?)  (verify)

Nizatidine is a histamine H₂ receptor antagonist that inhibits stomach acid production, and is commonly used in the treatment of peptic ulcer disease and gastroesophageal reflux disease.^[2]

It was patented in 1980 and approved for medical use in 1988.^[3][4] It was developed by Eli Lilly.

Medical use

Nizatidine is used to treat duodenal ulcers, gastric ulcers, and gastroesophageal reflux disease (GERD/GORD), and to prevent stress ulcers.^[5]

Adverse effects

Side effects are uncommon, usually minor, and include diarrhea, constipation, fatigue, drowsiness, headache, and muscle aches.^[5]

History and development

Nizatidine was developed by Eli Lilly, and was first marketed in 1988.^[3] It is considered to be equipotent with ranitidine and differs by the substitution of a thiazole ring in place of the furan ring in ranitidine. In September 2000, Eli Lilly announced they would sell the sales and marketing rights for Axid to Reliant Pharmaceuticals.^[6] Subsequently, Reliant developed the oral solution of Axid, marketing this in 2004, after gaining approval from the U.S. Food and Drug Administration (FDA).^[7] However, a year later, they sold rights of the Axid Oral Solution (including the issued patent^[8] protecting the product) to Braintree Laboratories.^[9]

Society and culture

Brand names

Brand names include Tazac and Axid.

References